Seer, Inc. (NASDAQ:SEER) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in shares of Seer, Inc. (NASDAQ:SEER) by 5.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 446,329 shares of the company’s stock after purchasing an additional 25,002 shares during the period. Geode Capital Management LLC owned 0.73% of Seer worth $879,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of SEER. Acadian Asset Management LLC raised its holdings in Seer by 35.5% in the 2nd quarter. Acadian Asset Management LLC now owns 1,802,106 shares of the company’s stock valued at $3,024,000 after acquiring an additional 472,283 shares during the last quarter. American Century Companies Inc. raised its holdings in Seer by 42.1% in the 2nd quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock valued at $104,000 after acquiring an additional 18,302 shares during the last quarter. Point72 DIFC Ltd acquired a new position in Seer in the 2nd quarter valued at $35,000. Cubist Systematic Strategies LLC acquired a new position in Seer in the 2nd quarter valued at $133,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Seer in the 2nd quarter valued at $148,000. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Seer Stock Performance

Shares of SEER opened at $2.40 on Friday. The stock has a fifty day moving average of $2.36 and a two-hundred day moving average of $1.99. The company has a market capitalization of $141.52 million, a PE ratio of -1.85 and a beta of 1.57. Seer, Inc. has a fifty-two week low of $1.51 and a fifty-two week high of $2.63.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.